Imaging agents for detecting neurological disorders
申请人:Gangadharmath Umesh B.
公开号:US20100239496A1
公开(公告)日:2010-09-23
Imaging agents of formula (I) and methods for detecting neurological disorders comprising administering to a patient in need compounds of formula (I) capable of binding to tau proteins and β-amyloid peptides are presented herein. The invention also relates to methods of imaging Aβ and tau aggregates comprising introducing a detectable quantity of pharmaceutical formulation comprising a radiolabeled compound of formula (I) and detecting the labeled compound associated with amyloid deposits and/or tau proteins in a patient. These methods and compositions enable preclinical diagnosis and monitoring progression of AD and other neurological disorders.
Ligand-Free Pd/C-Catalyzed One-Pot, Three-Component Synthesis of Aryl-Substituted Benzimidazoles by Hydrogen-Transfer and Suzuki Reactions in Water
作者:Chen Xu、Zhi-Qiang Xiao、Hong-Mei Li、Xin Han、Zhi-Qiang Wang、Wei-Jun Fu、Bao-Ming Ji、Xin-Qi Hao、Mao-Ping Song
DOI:10.1002/ejoc.201501169
日期:2015.12
An efficient protocol for the ligand-free and heterogeneous Pd/C-catalyzed one-pot, three-componentsynthesis of aryl-substituted benzimidazoles from benzyl alcohols by using water as the solvent was developed. The reaction involves hydrogen-transfer and Suzuki reactions. This method is quite convenient and environmentally friendly.
Imaging Agents for Detecting Neurological Disorders
申请人:Szardenings Anna Katrin
公开号:US20110182812A1
公开(公告)日:2011-07-28
Imaging agents of formulas (I)-(V) and methods for detecting neurological disorders comprising administering to a patient in need compounds of formulas (I)-(V) capable of binding to tau proteins and β-amyloid peptides are presented herein. The invention also relates to methods of imaging Aβ and tau aggregates comprising introducing a detectable quantity of pharmaceutical formulation comprising a radiolabeled compound of formulas (I)-(V) and detecting the labeled compound associated with amyloid deposits and/or tau proteins in a patient. These methods and compositions enable preclinical diagnosis and monitoring progression of AD and other neurological disorders.